Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Van Gundy, M. Liu, B. Sullivan, R. Riese, J. Teeter (Fresno, Baltimore, MD, New London, CT, United States Of America). Effect of inhaled human insulin (EXUBERA®; EXU) vs subcutaneous insulin (SC) on lung lining fluid constituents in adults with type 1 diabetes mellitus (T1DM). Eur Respir J 2007; 30: Suppl. 51, 4554

Member's Comments

No comment yet.

Related content which might interest you: Effect of roflumilast (ROF) on glucose levels in patients with COPD and diabetes mellitus type 2 (DM2) Source: Annual Congress 2010 - COPD: management Year: 2010 Inhaled insulin does not induce immediate airway responsiveness in patients with type 1 diabetes mellitus Source: Eur Respir J 2005; 26: Suppl. 49, 582s Year: 2005 Can new criteria for impaired fasting glucose (IFG) replace oral glucose testing (OGT) for cystic fibrosis-related diabetes (CFRD)? Source: Eur Respir J 2004; 24: Suppl. 48, 616s Year: 2004 Insulin therapy increases airway responsiveness in type 2 diabetes patients Source: Annual Congress 2008 - Cough and airway hyperresponsiveness Year: 2008 Pulmonary function of inhaled human insulin (Exubera®) in patients with type 2 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 742s Year: 2006 Pulmonary function of inhaled human insulin (Exubera®) in patients with type 1 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006 Influence of the glycaemic control [HbA1c] on sleep disorders reported by 261 obese type 2 diabetic patients Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008 The conjunctival microcirculation disturbances at COPD patients in combination with diabetes mellitus type 2 and their correction by gliclazide Source: Eur Respir J 2004; 24: Suppl. 48, 61s Year: 2004 Effect of duration of smoking cessation on the absorption of inhaled human insulin (Exubera®) Source: Eur Respir J 2006; 28: Suppl. 50, 390s Year: 2006 The influence of diabetes type 2 (D2) on pulmonary hypertension (PH) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 60s Year: 2005 New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis Source: Eur Respir J 2005; 25: 715-717 Year: 2005 Inadequate glucose control in type 2 diabetes is associated with impaired lung function and with systemic inflammation Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009 Characterizing the effects of inhaled human insulin (Exubera®) on FEV1 using disease progression modeling Source: Eur Respir J 2006; 28: Suppl. 50, 614s Year: 2006 Study of the connection between COPD, bronchial asthma and diabetes mellitus types 1 and 2 Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009 FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 840s Year: 2006 The relationship between lung function and blood glucose control in type 2 diabetic patients Source: Annual Congress 2008 - Lung function, airways and cough Year: 2008 Metabolic syndrome and diabetes mellitus in COPD Source: Eur Respir Mon 2013; 59: 117-134 Year: 2013 Role of BMI in the clinical course of COPD patients with type 2 diabetes mellitus Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes Source: Eur Respir J 2008; 32: 180-188 Year: 2008 Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin Source: Eur Respir J 2004; 24 : 552-558 Year: 2004